A Boston startup is launching what it says is the first at-home tick test available to U.S. consumers, giving families, hikers and pet owners a way to check within minutes whether a removed tick carries the bacteria that causes Lyme disease.
LymeAlert, founded by physician associate Erin Dawicki along with Michelle Ewy and Brenda Ong, begins shipping its $50 test kits this month. Rather than testing the person who was bitten, the kit analyzes the tick itself. Users place the tick into a sealed chamber, crush it using a built-in mechanism, add a processing solution and insert a test strip. Results are available in about 15 to 30 minutes, with a color change indicating whether Borrelia burgdorferi, the bacterium responsible for Lyme disease, is detected.
The company is targeting one of the biggest challenges in Lyme disease: time. Physicians may recommend a preventive dose of doxycycline within 72 hours of certain high-risk tick bites, making quick information valuable while medical decisions are still possible.
The market opportunity is substantial, particularly across the Northeast and Mid-Atlantic. An estimated 31 million Americans are bitten by ticks each year, while roughly 476,000 people receive treatment for Lyme disease annually. New York, New Jersey and Connecticut remain among the nation’s highest-risk states. Earlier this year, the Centers for Disease Control and Prevention reported that emergency department visits related to tick-borne illnesses reached their highest level since 2017.
Beyond the testing kit, LymeAlert is building a broader technology platform. Its companion smartphone app verifies test-strip results, directs users toward medical or veterinary care when appropriate, and anonymously maps where infected ticks are being found. The company plans to make aggregated hotspot information publicly available through the app, potentially creating one of the country’s largest real-time datasets on infected tick activity.
The startup emerged from the Massachusetts Institute of Technology’s Sloan School of Management and has attracted backing from Bay Area Lyme Ventures, an impact fund focused on tick-borne disease technologies. Initial sales will be made through the company’s website, selected REI stores in Massachusetts and New Hampshire, and independent pet retailers, with veterinary pilots already underway.
The launch also enters an area of ongoing medical debate. The CDC does not recommend relying on tick testing alone because a positive result does not mean a person was infected, while a negative result cannot rule out disease if another infected tick was involved. Health experts continue to advise that anyone with concerns after a tick bite should consult a healthcare provider, regardless of the test outcome.
For consumers, the product represents a new source of information rather than a diagnosis. For investors and the healthcare industry, LymeAlert’s larger opportunity may lie in building a nationwide surveillance platform that tracks where disease-carrying ticks are spreading as climate and habitat changes continue to expand their range.
JBizNews Desk | New York
© JBizNews.com — All Rights Reserved. Reproduction or distribution without written permission is prohibited.
